The National Institute on Aging and the Alzheimer’s Association (NIA-AA) research framework recommends the use of biomarker criteria for amyloid pathology, tau pathology, and neurodegeneration [AT(N)] for a biological definition of AD [10]. The gene discussed is MAPT; the disease is Alzheimer disease.